Risankizumab in IBD: Effective but Evidence Uneven Across CD and UC
This qualitative systematic review consolidates trial and real-world data on the selective interleukin-23 (IL-23) inhibitor risankizumab across Crohn disease and ulcerative colitis, but offers no pooled estimates for pharmacists to quantify effect.
📅 Journal publication: Aug 28, 2026·Last updated: Oct 7, 2026
Risankizumab shows promise for challenging Crohn's and colitis cases.
Crohn disease (CD) and ulcerative colitis (UC) often have poor responses to existing biologics, necessitating new treatment options. Risankizumab (RZB) showed high clinical remission and endoscopic healing rates in CD and significant remission rates in UC, with mostly mild adverse events. RZB provides a new therapeutic option for moderate-to-severe CD and UC, especially for patients unresponsive to other biologics; long-term safety data are still needed. RZB is effective for CD and UC with promising safety, especially for biologic-refractory cases.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Afzal MW, Haseeb A, Ali U, Ashraf MR, Mehmood A, Perveen A
Citation:Afzal MW, Haseeb A, Ali U, et al. Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review. Medicine. 2026;105(35):e50434. doi:10.1097/MD.0000000000050434
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.